Alnylam Pharmaceuticals Deal History & Licensing Activity
Alnylam Pharmaceuticals is a large biotech headquartered in US. Over the past three years, Alnylam Pharmaceuticals has been involved in 6 licensing and acquisition transactions, with a primary focus on RNAi (3 deals). The company currently has 24 active clinical trials, primarily in Cardiovascular.
Deals (12mo)
3
Active Trials
24
Top Modality
RNAi
Focus Area
Cardiovascular
Alnylam Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alnylam Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Alnylam Pharmaceuticals Inc. | Gene Therapy | Discovery | collaboration | Mar 2026 |
Alnylam Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Alnylam Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Alnylam Pharmaceuticals Strategic Signals
Key indicators of Alnylam Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Alnylam Pharmaceuticals Clinical Pipeline
Alnylam Pharmaceuticals has 24 active clinical trials across 5 development phases.
6
Unknown
1
Not Applicable
8
Phase 1
3
Phase 2
6
Phase 3
See How Your Asset Matches Alnylam Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
RNAi Benchmarks
Upfront, milestone, and royalty benchmarks for rnai deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Alnylam Pharmaceuticals Licensing & Deal Activity
Alnylam Pharmaceuticals is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Alnylam Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alnylam Pharmaceuticals include Cardiovascular (15 deals and trials), CNS Disorders (5 deals and trials), Rare Disease (1 deal and trial), and Immunology (1 deal and trial). In terms of modality, Alnylam Pharmaceuticals has shown particular interest in rnai, gene therapy, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alnylam Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Alnylam Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.